Oric Pharmaceuticals' (ORIC) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Oric Pharmaceuticals' stock has a "sell (D-)" rating reiterated by Weiss Ratings, indicating negative sentiment among analysts.
• Despite the negative rating from Weiss, several other analysts have issued "buy" ratings, with a consensus target price of $17.29.
• Insider trading activity shows significant sales, with the CEO and CFO selling shares and insiders selling a total of 261,000 shares recently.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

ORIC has been the topic of a number of other reports. Guggenheim initiated coverage on shares of Oric Pharmaceuticals in a research note on Thursday, September 4th. They issued a "buy" rating and a $18.00 price objective on the stock. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They set a "buy" rating and a $15.00 price target for the company. JPMorgan Chase & Co. cut their target price on Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, August 14th. HC Wainwright decreased their target price on Oric Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Finally, Zacks Research raised Oric Pharmaceuticals to a "hold" rating in a research note on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.29.

Oric Pharmaceuticals Trading Up 5.5%

NASDAQ ORIC opened at $13.10 on Friday. The firm has a market capitalization of $1.27 billion, a PE ratio of -6.93 and a beta of 1.68. The business's 50-day moving average price is $11.40 and its two-hundred day moving average price is $9.31. Oric Pharmaceuticals has a 12 month low of $3.90 and a 12 month high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). As a group, analysts forecast that Oric Pharmaceuticals will post -2.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jacob Chacko sold 37,461 shares of Oric Pharmaceuticals stock in a transaction on Monday, October 6th. The shares were sold at an average price of $12.32, for a total value of $461,519.52. Following the completion of the sale, the chief executive officer owned 531,419 shares of the company's stock, valued at approximately $6,547,082.08. This trade represents a 6.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Dominic Piscitelli sold 11,000 shares of the business's stock in a transaction on Monday, October 6th. The shares were sold at an average price of $14.52, for a total transaction of $159,720.00. Following the sale, the chief financial officer owned 48,317 shares of the company's stock, valued at $701,562.84. This trade represents a 18.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 261,000 shares of company stock valued at $3,024,703 in the last three months. Insiders own 6.82% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Oric Pharmaceuticals by 2.9% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company's stock valued at $497,000 after buying an additional 1,358 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its position in Oric Pharmaceuticals by 35.9% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company's stock valued at $53,000 after acquiring an additional 1,372 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Oric Pharmaceuticals by 17,300.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company's stock valued at $25,000 after purchasing an additional 2,422 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Oric Pharmaceuticals by 7.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 38,864 shares of the company's stock worth $394,000 after purchasing an additional 2,706 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Oric Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock worth $226,000 after purchasing an additional 3,131 shares in the last quarter. 95.05% of the stock is owned by institutional investors.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.